RCS - Incanthera PLC - AGM 2025 Presentation Materials

RNS Number : 8901G Incanthera PLC 10 November 2025 10 November 2025Incanthera plc("Incanthera" the "Company")AGM 2025 Presentation MaterialsIncanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology is pleased to advise that, following its AGM on Friday 7 November 2025, a recording of the meeting is now live on the Company's website, alongside the presentation given at the AGM.The recording and presentation can be accessed from the company's website here: https://www.incanthera.com/investors/results-reports-and-presentations/https://www.youtube.com/watch?v=ZQOFpD87LocFor further information please contact:Incanthera plcwww.incanthera.comTim McCarthy, Chairmantim.mccarthy@incanthera.comSimon Ward, Chief Executive Officersimon.ward@incanthera.comSuzanne Brocks, Head of Communicationssuzanne.brocks@incanthera.com+44 (0) 7831 675747+44 (0) 7747 625506+44 (0) 7776 234600Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLPJo Turner / Liam Murray / Ed Downes+44 (0) 20 7213 0880Broker: Stanford Capital Partners LtdPatrick Claridge / Bob Pountney+44 (0) 20 3650 3650/51Notes to EditorsAbout Incanthera plcIncanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology, delivering treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy.Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform.The Company's current focus is Skin + CELL, Incanthera's unique luxury skincare brand in a range of dermatological applications to meet currently unmet needs in the skincare market.For more information on the Company please visit: www.incanthera.com@incantheraplcAbout Skin + CELL Skin + CELL is Incanthera's luxury skincare brand utilising, launched in August 2025. Our ground-breaking formulation and delivery expertise brings scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.www.skinandcell.comThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NRAFBLFFEFLBFBB